June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Latanoprost eye drops increases interleukine-33 in mice eyes
Author Affiliations & Notes
  • Alexis Galeno Matos
    Ribeirão Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
  • Jhimmy Talbot
    Ribeirão Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
  • Raphael Peres
    Ribeirão Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
  • Larissa Domenegueti Ferreira
    Ribeirão Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
  • Jose Carlos Alves Filho
    Ribeirão Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
  • Jayter Silva Paula
    Ribeirão Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
  • Footnotes
    Commercial Relationships Alexis Matos, None; Jhimmy Talbot, None; Raphael Peres, None; Larissa Domenegueti Ferreira, None; Jose Filho, None; Jayter Paula, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3483. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Alexis Galeno Matos, Jhimmy Talbot, Raphael Peres, Larissa Domenegueti Ferreira, Jose Carlos Alves Filho, Jayter Silva Paula; Latanoprost eye drops increases interleukine-33 in mice eyes. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3483.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Long-term use of topical antiglaucoma drugs is associated with ocular surface inflammation and is a risk factor for trabeculectomy failure. Interleukine-33 (IL-33) is a member of the IL-1 family of cytokines and has been associated with the perpetuation of pro-inflammatory processes.

 
Methods
 

Latanoprost (0.05 mg/ml, 4 μl; N=12) or phosphate buffered saline (PBS, 4 μl, N=12) eye drops were applied to the right eye of C57BL/6 mice once a day for 10 days. After euthanasia, samples of cornea and conjunctiva were collected, at 5th and 10th day, for ELISA for IL-6 and IL-33. IL-33, IL-6 and TNF-alpha were also measured with ELISA in samples from mice 3T3 fibroblasts cultured in DMEM. These cells were treated, after reaching 80% confluence at third passage, with HBSS-Hanks added or not to latanoprost 0.05 mg/ml, for 60 min and were analyzed after 24 hours. Data were presented as mean±SEM and compared using the Student t test.

 
Results
 

In vivo treatment with latanoprost increased IL-6 levels (91.3±4.9 pg/mg vs 140.9±14.7 pg/mg; p=0.0123) and decreased IL-33 levels (159.4 ±4.1 pg/mg vs 102.7 ± 17.9 pg/mg; p= 0.004) at 5th day. However, at 10th day, both IL-33 and IL-6 levels were increased, but not significantly. 3T3 fibroblasts treated with latanoprost showed significant higher levels of IL-33 (0.03 ±0.01 pg/mg vs 0.67 ±0.36 pg/mg; p=0.019) and TNF-alpha (0.03 ±0.01 pg/mg vs 1.66 ±0.46; p=0.024) than controls. No significant difference was observed in the comparison of IL-6 levels in vitro.

 
Conclusions
 

The present findings confirmed the expression of pro-inflammatory mediators in the ocular surface due to the prostaglandin analog exposure and demonstrated for the first time the increased expression of IL-33 with latanoprost treatment. Although IL-33-producing fibroblasts might play a central role in the cicatrization process, the exact effects of IL-33 on the conjunctival healing process and the initial decrease in IL-33 levels deserve further explanation.  

 
Grafic 1. Determination by ELISA for levels of IL-6, TNF-alpha and IL-33 after 6 and 24 hours in culture samples fibroblast 3T3 cells, treated or not with PG analogues.
 
Grafic 1. Determination by ELISA for levels of IL-6, TNF-alpha and IL-33 after 6 and 24 hours in culture samples fibroblast 3T3 cells, treated or not with PG analogues.
 
 
Grafic 2 Determination by ELISA of IL-6 levels and IL-33 after 5 and 10 days, cornea and conjunctiva samples of mice treated or not with PG.
 
Grafic 2 Determination by ELISA of IL-6 levels and IL-33 after 5 and 10 days, cornea and conjunctiva samples of mice treated or not with PG.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×